Transdermal patch for delivering volatile liquid drugs

a technology of volatile liquid drugs and patches, which is applied in the direction of bands, dressings, organic active ingredients, etc., can solve the problems that the prior art does not teach or suggest the transdermal administration of mecamylamine itself to treat nicotine dependency, and the patent does not teach

Inactive Publication Date: 2005-12-13
ELAN PHRMA INT LTD +1
View PDF32 Cites 174 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]d) a removable release liner layer underlying the acrylic adhesive layer, wherein the combined amount of drug in the silicone adhesive layer and the acrylic adhesive layer is sufficient to provide a therapeutically effective amount of drug to the patient.

Problems solved by technology

These patents do not teach or suggest the transdermal administration of mecamylamine itself to treat nicotine dependency.
Furthermore, the prior art does not teach that coadministration of mecamylamine and nicotine is especially effective as a smoking cessation aid specifically suited for women.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal patch for delivering volatile liquid drugs
  • Transdermal patch for delivering volatile liquid drugs
  • Transdermal patch for delivering volatile liquid drugs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation and Testing of Nicotine Patch

[0035]Nicotine was added to a hexane solution of Dow Corning BIO-PSA amine-compatible silicone pressure sensitive adhesive to a level of approximately 12% by weight based on the combined dry weight of adhesive and nicotine. The resulting hexane solution of adhesive and nicotine was coated onto a 3M Scotchpak 1109 polyester / polyolefin backing at 13.8 mg / cm2 (1.63 mg / cm2 nicotine and 12.17 mg / cm2 adhesive) and the coated backing was dried at 30° C. to 40° C. for about 3 min.

[0036]National Starch DuroTak 87 2194 acrylic solution pressure sensitive adhesive was coated onto a 125 micron thick Daubert Coater Products 1-5 PESTR (Matte)-164Z siliconized polyester release liner at 13.18 mg / cm2 and the coated release liner was dried at 100° C. for about 10 min.

[0037]The dried silicone adhesive / nicotine-coated backing layer subassembly was then laminated to the dried acrylic adhesive-coated release liner subassembly to form a four-layer laminated compos...

example 2

Preparation and Testing of Nicotine / Mecamylamine Patches

[0040]Nicotine and mecamylamine were added to a hexane solution of Dow Corning BIO-PSA amine compatible silicone pressure sensitive adhesive. Two batches were made: one contained approximately 10% nicotine and 6.4% mecamylamine based on the total dry weight of the adhesive and the two drugs; and a second contained approximately 10% nicotine and 4.2% mecamylamine, based on the total dry weight of the adhesive and the two drugs. The batches were separately coated onto a 3M Scotchpak 1109 polyester / polyoefin backing film at 9.6 mg / cm2 (0.96 mg / cm2 nicotine, 0.61 mg / cm2 mecamylamine, 8.03 mg / cm2 adhesive for the first batch; 0.96 mg / cm2 nicotine, 0.40 mg / cm2 mecamylamine, 8.24 mg / cm2 adhesive for the second batch) and then dried at 30–40° C. for about 2 min.

[0041]A blend of two National Starch DuroTak acrylic solution polymers, 87-2196 and 87-2516, 25% and 75% w / w, respectively, was made. The blend was coated at 8.0 mg / cm2 onto a 7...

example 3

Preparation and Testing of Selegiline Patch

[0044]Selegiline was added to a hexane solution of Dow Corning BIO-PSA® amine-compatible silicone pressure sensitive adhesive to a concentration of approximately 10% by weight based on the combined dry weight of adhesive and selegiline. The resulting hexane solution of adhesive and selegiline was coated on 3M Scotchpak 1109 polyester / polyolefin backing at 10.0 mg / cm2 (1.0 mg / cm2 selegiline and 9.0 mg / cm2 adhesive) and the coated backing was dried at 300 C to 400 C for about 3 minutes.

[0045]National Starch DuroTak® 87-2194 acrylic solution pressure sensitive adhesive was coated onto a 125 micron thick Daubert Coated Products 1-5 PESTER (Matte)-164Z siliconized polyester release liner at 8.0 mg / cm2 and the coated release liner was dried at about 1000 C for about 10 minutes.

[0046]The dried silicone adhesive / selegiline-coated backing layer subassembly was then laminated to the dried acrylic adhesive-coated release liner subassembly to form a fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
boiling pointaaaaaaaaaa
boiling pointaaaaaaaaaa
Login to view more

Abstract

A transdermal patch for administering a volatile liquid drug, such as nicotine, transdermally to a patient comprising a four-layer laminated composite of: a top drug impermeable backing layer; a pressure sensitive silicone adhesive layer containing the drug; a pressure sensitive acrylic adhesive layer also containing the drug; and a removable siliconized release liner layer. Also disclosed is a method for treating a person for nicotine dependence and particularly for treating a woman for nicotine dependence.

Description

TECHNICAL FIELD[0001]This invention is in the field of transdermal drug delivery devices. More particularly, it relates to a method for making transdermal patches that deliver volatile liquid drugs, such as nicotine, mecamylamine and selegiline, and to the resulting patches. The invention also relates to a method for treating a person for nicotine dependence comprising transdermally administering an effective amount of mecamylamine to the person without transdermal coadministration of nicotine. The invention further relates to a method for treating women for nicotine dependence comprising transdermally co-administering effective doses of mecamylamine and nicotine.BACKGROUND ART[0002]There are two basic types of transdermal patches that are used to deliver liquid drugs. One is a liquid reservoir patch in which the liquid drug, either neat or dissolved in a carrier, is confined in a pouch or sac within the device. An example of such a device for delivering nicotine is shown in FIG. 1 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61F13/00A61F13/02A61K9/70A61K31/167A61K31/465A61L15/16
CPCA61K9/7061A61K9/7069A61K9/7092A61K31/167A61K31/465A61K2300/00
Inventor MIRANDA, JESUSBETLACH, II, CHARLES J.
Owner ELAN PHRMA INT LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products